Prescription Pattern of Empagliflozin and Linagliptin Combination among Indian Health Care Practitioners
Journal: International Journal of Science and Research (IJSR) (Vol.11, No. 1)Publication Date: 2022-01-05
Authors : Arora Saurabh; Chatterjee Amitesh K; Banerjee Mainak; Singh Anil K; Deshpande Suneel; Tandon Ashwani K; Pramod Pradeep J; Jain Pankaj; Singh Akash; Jayaprakash P; Mathur Rajwanth P; Basavaraj GS; Kumar Anshuman; Sonawane Ashutosh; Khalse Maneesha;
Page : 659-669
Keywords : empagliflozin; linagliptin; cardiovascular disease; renal disease; anti-hyperglycemic agents; diabetes;
Abstract
Diabetes mellitus is a growing threat in India. The South Asian phenotype, which predisposes to diabetes and cardiovascular disease, is characteristic of Indians. Prescribing Practice of Empagliflozin and Linagliptin in Indian Cardio-Diabetes Patients (PELICARD) evaluated the prescription of empagliflozin and linagliptin among Indian doctors, and elucidated the patient profile for which these drugs were used. DPP4 inhibitors and SGLT2 inhibitors were the preferred add-on drug class. Empagliflozin, linagliptin and their combination were commonly prescribed after using two other anti-hyperglycemic agents, after diabetes duration of 3-5 years, among patients aged 40-49 years, and at HbA1c 7-8%. Indian doctors perceive that empagliflozin and linagliptin may be better suited in the Indian population.
Other Latest Articles
- Biomedical Waste Management in India - A Review Article
- Morphological Variants and Dimensional Analysis of Human Acromion Process
- Probing the Issues of Illiteracy and Early Marriage in Malda District: A Village Study
- Character of Surpankha: A Journey of Marginalized Woman
- An Analysis of Sentencing under Indian Laws
Last modified: 2022-02-15 19:04:11